1. Inicio
  2. Publicaciones
  3. Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry

Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Gutierrez, MDA
  • Rubio-Rivas, M
  • Gomez, CR
  • Saez, AM
  • de Pedro, IP
  • Homs, N
  • Garcia, BA
  • Carvajal, CC
  • Fernandez, FA
  • Perez, JLB
  • Nunez, JAV
  • Gimenez, LL
  • Fernandez, CS
  • Bailon, MM
  • de Almeida, CT
  • Moraleja, JG
  • Garcia-Monge, MD
  • Amezua, CH
  • Montero, MDF
  • Galvan, VG
  • Saenz, JC
  • Boixeda, R
  • Rincon, JMR
  • Huelgas, RG

Grupos

Abstract

(1) Objectives: To describe the clinical characteristics and clinical course of hospitalized patients with COVID-19 and autoimmune diseases (ADs) compared to the general population. (2) Methods: We used information available in the nationwide Spanish SEMI-COVID-19 Registry, which retrospectively compiles data from the first admission of adult patients with COVID-19. We selected all patients with ADs included in the registry and compared them to the remaining patients. The primary outcome was all-cause mortality during admission, readmission, and subsequent admissions, and secondary outcomes were a composite outcome including the need for intensive care unit (ICU) admission, invasive and non-invasive mechanical ventilation (MV), or death, as well as in-hospital complications. (3) Results: A total of 13,940 patients diagnosed with COVID-19 were included, of which 362 (2.6%) had an AD. Patients with ADs were older, more likely to be female, and had greater comorbidity. On the multivariate logistic regression analysis, which involved the inverse propensity score weighting method, AD as a whole was not associated with an increased risk of any of the outcome variables. Habitual treatment with corticosteroids (CSs), age, Barthel Index score, and comorbidity were associated with poor outcomes. Biological disease-modifying anti-rheumatic drugs (bDMARDs) were associated with a decrease in mortality in patients with AD. (4) Conclusions: The analysis of the SEMI-COVID-19 Registry shows that ADs do not lead to a different prognosis, measured by mortality, complications, or the composite outcome. Considered individually, it seems that some diseases entail a different prognosis than that of the general population. Immunosuppressive/immunoregulatory treatments (IST) prior to admission had variable effects.

Datos de la publicación

ISSN/ISSNe:
2077-0383, 2077-0383

Journal of clinical medicine  MDPI AG

Tipo:
Article
Páginas:
-
PubMed:
33922777
Factor de Impacto:
1,040 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 9

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • autoimmune diseases; antirheumatic agents; biological therapy; glucocorticoids; immune system diseases; COVID-19; SARS-CoV-2

Campos de Estudio

Proyectos y Estudios Clínicos

SUBREGISTRO PROSPECTIVO, MULTICÉNTRICO Y OBSERVACIONAL DE SEGURIDAD POSTAUTORIZACIÓN PARA CARACTERIZAR EL PERFIL DE SEGURIDAD A LARGO PLAZO DEL USO COMERCIAL DE ELIGLUSTAT (CERDELGA®) EN PACIENTES ADULTOS CON ENFERMEDAD DE GAUCHER.

Investigador Principal: PATRICIA CORRECHER MEDINA

OBS14099 . 2018

MEMORIA PARA EL ESTUDIO DE ESPLENOMEGALIA Y PACIENTES ESPLENECTOMIZADOS NO FILIADOS EN POBLACIÓN INFANTIL Y ADULTA.

Investigador Principal: ISIDRO VITORIA MIÑANA

PREDIGA . 2020

ENSAYO CLINICO ALEATORIZADO PARA EVALUAR LA EFICACIA DE DIFERENTES TRATAMIENTOS EN PACIENTES CON COVID19 QUE REQUIEREN HOSPITALIZACION.

Investigador Principal: MARTA MONTERO ALONSO

PANCOVID . 2020

Cita

Compartir